大剂量舒肝解郁胶囊对冠心病PCI术后患者抑郁焦虑的疗效及血清单胺类神经递质的影响

Effect of large dose Shuganjieyu capsule on depression and anxiety and serum monoamine neurotransmitters in patients with coronary heart disease after PCI

目的 观察大剂量舒肝解郁胶囊对冠心病经皮冠状动脉介入治疗(Percutaneous coronary intervention,PCI)术后患者抑郁共病焦虑的疗效及对血清单胺类神经递质的影响。方法 按随机数字表法将纳入的90例患者分成观察组(45例)和对照组(45例),观察组给予大剂量舒肝解郁胶囊治疗,对照组给予常规剂量舒肝解郁胶囊治疗。比较两组的治疗效果。结果 治疗前观察组和对照组基线情况无显著差异;经治疗8周后,观察组较对照组汉密尔顿抑郁量表-24、汉密尔顿焦虑量表评分有显著差异(P<0.05),多巴胺、5羟色胺、去甲肾上腺素水平有显著差异(P<0.05),两组不良反应发生率比较无显著差异(P<0.05)。结论 大剂量舒肝解郁胶囊能更有效调节冠心病PCI术后抑郁共病焦虑患者的单胺类神经递质水平,更大程度改善抑郁焦虑症状,不良反应少。

Objective To observing the therapeutic effect of high-dose Shugan Jieyu capsules on postoperative depression comorbidity anxiety and serum monoamine neurotransmitters in patients with coronary heart disease undergoing percutaneous coronary intervention(PCI).Methods According to the random number table method,the 90 patients included were divided into an observation group(45 cases)and a control group(45 cases).The observation group was treated with high-dose Shuganjieyu Capsules,while the control group was treated with conventional dose Shuganjieyu Capsules.Compare the treatment effects of the two groups.Results There was no significant difference in baseline conditions between the observation group and the control group before treatment.After 8 weeks of treatment,there was a significant difference in the Hamilton Depression Scale 24 and Hamilton Anxiety Scale scores between the observation group and the control group(P<0.05).There was a significant difference in the levels of dopamine,serotonin,and norepinephrine(P<0.05),and there was no significant difference in the incidence of adverse reactions between the two groups(P<0.05).Conclusion High dose Shugan Jieyu Capsules can more effectively regulate the levels of monoamine neurotransmitters in patients with comorbid depression and anxiety after coronary heart disease PCI,improve symptoms of depression and anxiety to a greater extent,and have fewer adverse reactions.